Form 4: Axogen Director Sells Shares to Cover Tax Obligations
Insider Transaction Report
Axogen, Inc. Director Amy McBride Wendell sold 4,073 shares of common stock on June 9, 2025, at a weighted average price of $10.61 per share to satisfy tax obligations related to restricted stock unit vesting.
Summary
- Amy McBride Wendell, a Director of Axogen, Inc. (AXGN), reported a transaction on June 9, 2025.
- The transaction involved the sale of 4,073 shares of Axogen Common Stock.
- The shares were sold at a weighted average price of $10.61 per share, with prices ranging from $10.47 to $10.61.
- Following this transaction, Amy McBride Wendell beneficially owns 93,826 shares of Axogen Common Stock.
- The sale was conducted to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale by a director to cover tax obligations associated with restricted stock unit vesting, which is a common and expected event for insiders.
Negatives
- A director, Amy McBride Wendell, reduced her direct beneficial ownership in Axogen, Inc. by 4,073 shares.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This Form 4 filing reports a routine insider stock transaction, which is specific to Axogen, Inc. and its director's personal financial planning. It does not provide information relevant to broader industry trends or competitive dynamics within the medical device or regenerative medicine sectors.
Stakeholder Impact
- Shareholders: The sale represents a minor reduction in a director's direct ownership, but given the stated reason (tax obligations), it is unlikely to significantly impact shareholder confidence or the company's valuation.
- Employees: No direct impact on employees is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 06/09/2025 | Date of transaction where shares were sold. |
| 06/11/2025 | Date the Form 4 was filed with the SEC. |
Recommendation
holdKeywords
Axogen, AXGN, Form 4, Insider Transaction, Stock Sale, Director, Restricted Stock Units, Tax Obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.